Drug Trial Radar · NCT01718288
Optimization of Treatment in Patients With Severe Peripheral Ischemia (Fontaine Stage IIb)
Last checked: Nov 20, 2026Latest source record: Oct 31, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Nov 2006
Primary completion
Mar 2011
Study completion Apr 2012
Sponsor
- Lead sponsor
- Fadoi Foundation, ItalyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 31, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the possibility of optimization of therapy with prostanoids (iloprost), in patients with Fontaine's stage IIb severe chronic ischemia, both in patients eligible for surgery both in patients for which it is only possible medical therapy
Conditions
- Peripheral Arterial Disease
Interventions
iloprostDrug
The study, consists of two substudies, which deal with patients susceptible to medical therapy alone (substudy 1) or treated with classical surgical therapy (substudy 2). For each substudy, pts will be divided into two groups, one that will receive conventional treatments but not prostanoids, other conventional treatments with addition of iloprost. The 4 groups: 1A. Pts unsuitable to surgical or endovascular vascular therapy: conventional treatment 1. B. Pts unsuitable to surgical or endovascular vascular therapy: treatment with iloprost plus conventional treatment 2. A. Pts suitable to vascular surgical or endovascular therapy: conventional treatment 2B. Pts suitable to vascular surgical or endovascular therapy: treatment with iloprost plus conventional treatment
Standard Treatment (aspirin.....),Drug
The standard treatment, as has already been explained in the submission is the best treatment that the guidelines suggest for that specific type of patient with those complications and with stage 2b severe PAD. correction of concomitant risk factors, physical exercise, antiplatelet, standard heparin /low molecular weight heparin, hemorheological/vasodilators such as pentoxifylline/buflomedil, propionyl-L-carnitine, Defibrotide) but not prostanoids
Primary outcomes
What the sponsor says the trial is designed to measure.
- Measure of PFWD(pain-free walking distance)in patients with 2b stage PADTime frame: 13 months
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Internal Medicine, Hospital "Policlinico"
Bari, Italy
Angiology, Hospital "Ferrarotto - Alessi"
Catania, Italy
Internal Medicine, Hospital "Pugliese - Ciaccio"
Catanzaro, Italy
Internal Medicine, Hospital of Fermo
Fermo, Italy
Vascular Surgery, Hospital "Galliera"
Genoa, Italy
Internal Medicine, Hospital Civile
Legnano, Italy
Internal Medicine, "Madonna delle Grazie" Hospital
Matera, Italy
Internal Medicine, Hospital "Fatebenefratelli"
Naples, Italy
Surgery Dept., Hospital " San Giovanni Bosco"
Naples, Italy
Internal Medicine, Hospital "Bianchi Melacrino Morelli"
Reggio Calabria, Italy
Internal Medicine, Hospital Policlinico Campus Biomedico
Rome, Italy
Internal Medicine, Hospital "Fondazione Circolo Macchi"
Varese, Italy
Internal Medicine, Hospital "Jazzolino"
Vibo Valentia, Italy
Angiology, Hospital "G. Fucito"
Mercato San Severino, Salerno, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.